Global Cancer Biopsy 麻豆原创 Research Report 2023

Publication ID:

PB502231059

Publication Date:

February 15, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

For most types of cancer, biopsy is the main way doctors diagnose cancer. A biopsy is a microscopic examination of a small amount of tissue. Other tests may indicate that cancer exists, but only biopsy can make a definite diagnosis.
Highlights
The global Cancer Biopsy market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Cancer Biopsy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Cancer Biopsy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Cancer Biopsy in Breast Cancer is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Cancer Biopsy include Qiagen N.V., Illumina, Inc., ANGLE Plc, Myriad Genetics, Hologic, Inc., Biocept, Inc., Thermo Fisher Scientific, Inc., Danaher and Lucence Diagnostics Pte. Ltd., etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cancer Biopsy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Biopsy.
The Cancer Biopsy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Cancer Biopsy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Biopsy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Qiagen N.V.
Illumina, Inc.
ANGLE Plc
Myriad Genetics
Hologic, Inc.
Biocept, Inc.
Thermo Fisher Scientific, Inc.
Danaher
Lucence Diagnostics Pte. Ltd.
GRAIL, Inc.
Guardant Health
Exact Sciences Corporation
Freenome Holdings, Inc.
Oncimmune
Chronix Biomedical, Inc.
Personal Genome Diagnostics Inc.
Segment by Type
Tissue Biopsies
Liquid Biopsies
Others
Segment by Application
Breast Cancer
Colorectal Cancer
Cervical Cancers
Lung Cancers
Prostate Cancers
Skin Cancers
Blood Cancers
Kidney Cancers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer Biopsy companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Cancer Biopsy 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Tissue Biopsies
1.2.3 Liquid Biopsies
1.2.4 Others
1.3 麻豆原创 by Application
1.3.1 Global Cancer Biopsy 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Breast Cancer
1.3.3 Colorectal Cancer
1.3.4 Cervical Cancers
1.3.5 Lung Cancers
1.3.6 Prostate Cancers
1.3.7 Skin Cancers
1.3.8 Blood Cancers
1.3.9 Kidney Cancers
1.3.10 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cancer Biopsy 麻豆原创 Perspective (2018-2029)
2.2 Cancer Biopsy Growth Trends by Region
2.2.1 Global Cancer Biopsy 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Cancer Biopsy Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Cancer Biopsy Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Cancer Biopsy 麻豆原创 Dynamics
2.3.1 Cancer Biopsy Industry Trends
2.3.2 Cancer Biopsy 麻豆原创 Drivers
2.3.3 Cancer Biopsy 麻豆原创 Challenges
2.3.4 Cancer Biopsy 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cancer Biopsy Players by Revenue
3.1.1 Global Top Cancer Biopsy Players by Revenue (2018-2023)
3.1.2 Global Cancer Biopsy Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Cancer Biopsy 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cancer Biopsy Revenue
3.4 Global Cancer Biopsy 麻豆原创 Concentration Ratio
3.4.1 Global Cancer Biopsy 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer Biopsy Revenue in 2022
3.5 Cancer Biopsy Key Players Head office and Area Served
3.6 Key Players Cancer Biopsy Product Solution and Service
3.7 Date of Enter into Cancer Biopsy 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Cancer Biopsy Breakdown Data by Type
4.1 Global Cancer Biopsy Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Cancer Biopsy Forecasted 麻豆原创 Size by Type (2024-2029)
5 Cancer Biopsy Breakdown Data by Application
5.1 Global Cancer Biopsy Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Cancer Biopsy Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Cancer Biopsy 麻豆原创 Size (2018-2029)
6.2 North America Cancer Biopsy 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Cancer Biopsy 麻豆原创 Size by Country (2018-2023)
6.4 North America Cancer Biopsy 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cancer Biopsy 麻豆原创 Size (2018-2029)
7.2 Europe Cancer Biopsy 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Cancer Biopsy 麻豆原创 Size by Country (2018-2023)
7.4 Europe Cancer Biopsy 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cancer Biopsy 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Cancer Biopsy 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Cancer Biopsy 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Cancer Biopsy 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cancer Biopsy 麻豆原创 Size (2018-2029)
9.2 Latin America Cancer Biopsy 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Cancer Biopsy 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Cancer Biopsy 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cancer Biopsy 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Cancer Biopsy 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Cancer Biopsy 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Cancer Biopsy 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Qiagen N.V.
11.1.1 Qiagen N.V. Company Detail
11.1.2 Qiagen N.V. Business Overview
11.1.3 Qiagen N.V. Cancer Biopsy Introduction
11.1.4 Qiagen N.V. Revenue in Cancer Biopsy Business (2018-2023)
11.1.5 Qiagen N.V. Recent Development
11.2 Illumina, Inc.
11.2.1 Illumina, Inc. Company Detail
11.2.2 Illumina, Inc. Business Overview
11.2.3 Illumina, Inc. Cancer Biopsy Introduction
11.2.4 Illumina, Inc. Revenue in Cancer Biopsy Business (2018-2023)
11.2.5 Illumina, Inc. Recent Development
11.3 ANGLE Plc
11.3.1 ANGLE Plc Company Detail
11.3.2 ANGLE Plc Business Overview
11.3.3 ANGLE Plc Cancer Biopsy Introduction
11.3.4 ANGLE Plc Revenue in Cancer Biopsy Business (2018-2023)
11.3.5 ANGLE Plc Recent Development
11.4 Myriad Genetics
11.4.1 Myriad Genetics Company Detail
11.4.2 Myriad Genetics Business Overview
11.4.3 Myriad Genetics Cancer Biopsy Introduction
11.4.4 Myriad Genetics Revenue in Cancer Biopsy Business (2018-2023)
11.4.5 Myriad Genetics Recent Development
11.5 Hologic, Inc.
11.5.1 Hologic, Inc. Company Detail
11.5.2 Hologic, Inc. Business Overview
11.5.3 Hologic, Inc. Cancer Biopsy Introduction
11.5.4 Hologic, Inc. Revenue in Cancer Biopsy Business (2018-2023)
11.5.5 Hologic, Inc. Recent Development
11.6 Biocept, Inc.
11.6.1 Biocept, Inc. Company Detail
11.6.2 Biocept, Inc. Business Overview
11.6.3 Biocept, Inc. Cancer Biopsy Introduction
11.6.4 Biocept, Inc. Revenue in Cancer Biopsy Business (2018-2023)
11.6.5 Biocept, Inc. Recent Development
11.7 Thermo Fisher Scientific, Inc.
11.7.1 Thermo Fisher Scientific, Inc. Company Detail
11.7.2 Thermo Fisher Scientific, Inc. Business Overview
11.7.3 Thermo Fisher Scientific, Inc. Cancer Biopsy Introduction
11.7.4 Thermo Fisher Scientific, Inc. Revenue in Cancer Biopsy Business (2018-2023)
11.7.5 Thermo Fisher Scientific, Inc. Recent Development
11.8 Danaher
11.8.1 Danaher Company Detail
11.8.2 Danaher Business Overview
11.8.3 Danaher Cancer Biopsy Introduction
11.8.4 Danaher Revenue in Cancer Biopsy Business (2018-2023)
11.8.5 Danaher Recent Development
11.9 Lucence Diagnostics Pte. Ltd.
11.9.1 Lucence Diagnostics Pte. Ltd. Company Detail
11.9.2 Lucence Diagnostics Pte. Ltd. Business Overview
11.9.3 Lucence Diagnostics Pte. Ltd. Cancer Biopsy Introduction
11.9.4 Lucence Diagnostics Pte. Ltd. Revenue in Cancer Biopsy Business (2018-2023)
11.9.5 Lucence Diagnostics Pte. Ltd. Recent Development
11.10 GRAIL, Inc.
11.10.1 GRAIL, Inc. Company Detail
11.10.2 GRAIL, Inc. Business Overview
11.10.3 GRAIL, Inc. Cancer Biopsy Introduction
11.10.4 GRAIL, Inc. Revenue in Cancer Biopsy Business (2018-2023)
11.10.5 GRAIL, Inc. Recent Development
11.11 Guardant Health
11.11.1 Guardant Health Company Detail
11.11.2 Guardant Health Business Overview
11.11.3 Guardant Health Cancer Biopsy Introduction
11.11.4 Guardant Health Revenue in Cancer Biopsy Business (2018-2023)
11.11.5 Guardant Health Recent Development
11.12 Exact Sciences Corporation
11.12.1 Exact Sciences Corporation Company Detail
11.12.2 Exact Sciences Corporation Business Overview
11.12.3 Exact Sciences Corporation Cancer Biopsy Introduction
11.12.4 Exact Sciences Corporation Revenue in Cancer Biopsy Business (2018-2023)
11.12.5 Exact Sciences Corporation Recent Development
11.13 Freenome Holdings, Inc.
11.13.1 Freenome Holdings, Inc. Company Detail
11.13.2 Freenome Holdings, Inc. Business Overview
11.13.3 Freenome Holdings, Inc. Cancer Biopsy Introduction
11.13.4 Freenome Holdings, Inc. Revenue in Cancer Biopsy Business (2018-2023)
11.13.5 Freenome Holdings, Inc. Recent Development
11.14 Oncimmune
11.14.1 Oncimmune Company Detail
11.14.2 Oncimmune Business Overview
11.14.3 Oncimmune Cancer Biopsy Introduction
11.14.4 Oncimmune Revenue in Cancer Biopsy Business (2018-2023)
11.14.5 Oncimmune Recent Development
11.15 Chronix Biomedical, Inc.
11.15.1 Chronix Biomedical, Inc. Company Detail
11.15.2 Chronix Biomedical, Inc. Business Overview
11.15.3 Chronix Biomedical, Inc. Cancer Biopsy Introduction
11.15.4 Chronix Biomedical, Inc. Revenue in Cancer Biopsy Business (2018-2023)
11.15.5 Chronix Biomedical, Inc. Recent Development
11.16 Personal Genome Diagnostics Inc.
11.16.1 Personal Genome Diagnostics Inc. Company Detail
11.16.2 Personal Genome Diagnostics Inc. Business Overview
11.16.3 Personal Genome Diagnostics Inc. Cancer Biopsy Introduction
11.16.4 Personal Genome Diagnostics Inc. Revenue in Cancer Biopsy Business (2018-2023)
11.16.5 Personal Genome Diagnostics Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Qiagen N.V.
Illumina, Inc.
ANGLE Plc
Myriad Genetics
Hologic, Inc.
Biocept, Inc.
Thermo Fisher Scientific, Inc.
Danaher
Lucence Diagnostics Pte. Ltd.
GRAIL, Inc.
Guardant Health
Exact Sciences Corporation
Freenome Holdings, Inc.
Oncimmune
Chronix Biomedical, Inc.
Personal Genome Diagnostics Inc.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.